BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 6, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2008

View Archived Issues

ABT-335 and statin combinations effective in phase III dyslipidemia studies

Read More

Heart failure model reveals novel activity of inotropic agent CK-452

Read More

Follow-up data support effect of green tea catechins in preventing prostate cancer

Read More

Oral AS-606521 inhibits uterine activity in pregnant rhesus monkeys

Read More

Takeda joins an initiative to discover biomarkers

Read More

PharmaMar's Yondelis granted orphan drug status in Switzerland, EMEA approval for phase III trial

Read More

Recent Merck & Co. patent discloses new remedial options for glaucoma

Read More

Myostatin-inhibiting gene therapy shows benefit in a mouse model of Duchenne muscular dystrophy

Read More

Chronogen patent divulges new treatment alternatives for age-related disorders

Read More

Recent Dainippon Sumitomo patent describes novel therapeutic agents for dermatitis

Read More

Carfilzomib receives FDA orphan drug designation in multiple myeloma

Read More

Eisai to resume E-2012 clinical trial in Alzheimer's disease

Read More

New antiatherosclerotic agent reported in recent Merck & Co. patent

Read More

BioMarker Pharmaceuticals launches Gene Essence genome analysis test in the U.S.

Read More

Monogram enters agreement to provide resistance and tropism testing of Progenics' PRO-140

Read More

ISTA reports results from clinical trial of once-daily Xibrom for ocular inflammation

Read More

EMEA accepts for review Cell Therapeutics' MAA for Xyotax in NSCLC

Read More

U.S. phase III clinical trial of Kamada's intravenous AAT meets primary endpoint

Read More

Cosmo begins phase I trials of anti-androgen cream as skin disorder therapy

Read More

Meda files for European approval of BioDelivery Sciences' BEMA fentanyl

Read More

Teijin enters license agreement in Japan with Dong Wha for DW-1350 in osteoporosis

Read More

ProtAffin is awarded EUR 1.1 million research grant in Austria for development of PA-401

Read More

EnVivo initiates clinical safety and biomarker study of EVP-6124 in schizophrenia

Read More

The FDA accepts FibroGen's complete response for clinical holds of FG-2216 and FG-4592

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Illustration of liver being targets with cross-hairs

    Study identifies CAND1 as therapeutic target in hepatoblastoma

    BioWorld Science
    Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing